Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Multiple myeloma (MM) is an incurable blood cancer where tumors evade the immune system, limiting immunotherapy effectiveness.
• Identifying mechanisms of immune evasion is crucial for developing better MM treatments.

Purpose of the Study:

• To investigate the role of RNA editing enzyme ADAR1 in immune suppression within multiple myeloma.
• To explore the ADAR1-MDA5 signaling pathway as a potential therapeutic target for enhancing immunotherapy in MM.

Main Methods:

• Integrative analyses of bulk and single-cell transcriptomic datasets from MM patients.
• Functional studies involving ADAR1 knockdown and MDA5 depletion in MM models.
• In vivo studies using 8-azaadenosine to potentiate PD-1 blockade therapy.

Main Results:

• ADAR1 is upregulated in MM plasma cells, correlating with poor outcomes and reduced CD8+ T-cell infiltration.
• ADAR1 knockdown restores type I interferon signaling by increasing dsRNA-MDA5 association, boosting T-cell responses.
• In vivo, 8-azaadenosine combined with PD-1 blockade reduced tumor growth and enhanced anti-tumor immunity.

Conclusions:

• ADAR1-mediated RNA editing is a key mechanism of immune evasion in MM by inhibiting MDA5-dependent dsRNA sensing.
• The ADAR1-MDA5-type I interferon axis represents a promising therapeutic target to overcome immune suppression and improve immunotherapy for multiple myeloma.